Cytokines and hematopoietic stem cell mobilization

@article{Nervi2006CytokinesAH,
  title={Cytokines and hematopoietic stem cell mobilization},
  author={Bruno Nervi and Daniel C. Link and John F Dipersio},
  journal={Journal of Cellular Biochemistry},
  year={2006},
  volume={99}
}
Hematopoietic stem cell transplantation (HSCT) has become the standard of care for the treatment of many hematologic malignancies, chemotherapy sensitive relapsed acute leukemias or lymphomas, multiple myeloma; and for some non‐malignant diseases such as aplastic anemia and immunodeficient states. The hematopoietic stem cell (HSC) resides in the bone marrow (BM). A number of chemokines and cytokines have been shown in vivo and in clinical trials to enhance trafficking of HSC into the peripheral… 
New agents for mobilizing peripheral blood stem cells.
  • H. Greinix, N. Worel
  • Biology, Medicine
    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • 2009
Hematopoietic stem cell mobilization strategies to support high-dose chemotherapy: A focus on relapsed/refractory germ cell tumors
TLDR
The existing literature regarding studies reporting various HSC mobilization approaches in patients with relapsed/refractory GCTs are reviewed, newer experimental mobilization strategies employing novel agents that have been applied in other hematologic or solid malignancies are reported.
Physiology and Pharmacology of Plerixafor
  • S. Fricker
  • Biology, Medicine
    Transfusion Medicine and Hemotherapy
  • 2013
TLDR
The discovery of plerixafor, a selective inhibitor of CXCR4, has provided a new additional means of mobilizing HSC for autologous transplantation and rapidly mobilizes HSC within hours compared with the multi-day treatment required by G-CSF in mouse, dog and non-human primate.
Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4
TLDR
The development of small-molecule CXCR4 and VLA-4 inhibitors are discussed and how they may improve the utility and convenience of peripheral blood stem cell transplantation.
Mobilization of hematopoietic stem cells into the peripheral blood
TLDR
Hematopoietic stem cells can be mobilized out of the bone marrow into the blood for the reconstitution of hematopoiesis following high-dose therapy, and traditional methods include chemotherapy with or without myeloid growth factors.
Improving stem cell mobilization strategies: future directions
TLDR
Improved strategies to mobilize stem cells would increase the availability of auto-HSCT and optimize engraftment and outcomes in patients with multiple myeloma or chemosensitive relapsed high- or intermediate-grade non-Hodgkin's lymphoma.
Peripheral blood stem cells: mobilization strategies and potential therapeutic applications
TLDR
PBSC transplantation is now a day’s preferred transplantation source of stem cells as treatment modality for various hematologic malignancies, with the advantages of a shorter engraftment time and the lack of a need for surgical procedure necessary for bone marrow harvesting.
CXCR4 in clinical hematology.
TLDR
For patients with multiple myeloma and non-Hodgkin's Lymphoma, treatment with plerixafor, an inhibitor of CXCL12 binding to CXCR4, plus G- CSF mobilizes stem cells for autologous transplantation to a greater degree than the treatment with G-CSF alone, and in some cases when patients could not be mobilized with cytokines, chemotherapy, or the combination.
Advances in mobilization for the optimization of autologous stem cell transplantation
TLDR
The current methodologies to improve hematopoietic stem cell mobilization are discussed and a new agent, plerixafor added to G-CSF has been approved to enhance PBSC mobilization.
Factors influencing stem cell mobilization in patients with hematologic malignancies and solid tumors
TLDR
The aim of the study was to establish the influence of diagnosis, sex, age, number of previous courses of chemotherapy, mobilization regimen, and bone marrow involvement on the outcome of peripheral blood stem cell mobilization.
...
...

References

SHOWING 1-10 OF 121 REFERENCES
Hematopoietic Stem Cells Are Uniquely Selective in Their Migratory Response to Chemokines
TLDR
The sharply restricted chemotactic responsiveness of HSC is unique among leukocytes and may be necessary for the specific homing of circulating HSC to bone marrow, as well as for the maintenance of H SC in hematopoietic microenvironments.
Peripheral blood stem cell mobilization. A role for CXC chemokines.
Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies.
  • R. Brown, D. Adkins, J. Dipersio
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1997
TLDR
Following allogeneic PBSC transplant, patients who received greater than 5 x 10(6) CD34+ cells/ kg recipient weight had a high probability of rapid engraftment, which indicates that other, as yet unidentified, factors play an important role in determining the effectiveness of mobilization.
Allogeneic peripheral blood stem cell transplantation.
TLDR
Improved survival and disease-free survival and fewer relapses in recipients of PBSC as a result of improved immune reconstitution and a graft-vs-leukemia (GVL) effect are most apparent in patients with more advanced hematologic malignancies, but further studies are needed to define the relative benefits of PBSc for patients with less advanced disease.
Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist
TLDR
Results support the hypothesis that the CXCL12-CXCR4 axis is involved in marrow retention of HSCs and HPCs, and demonstrate the clinical potential of AMD3100 for HSC mobilization.
Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation.
TLDR
This randomized trial provides clinical evidence that the use of G-CSF alone is adequate for HPC mobilization, even in heavily pretreated patients with relapsed lymphoma.
CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.
TLDR
The findings demonstrated the importance of the SDF-1/CX CR4 axis in the regulation of in vivo motility and development of human AML stem cells and identified CXCR4 neutralization as a potential treatment for AML.
Cytokines and stem cell mobilization for autologous and allogeneic transplantation.
TLDR
Recent studies that advance the understanding of the biology of stem cell mobilization are reviewed and cytokines in current use and in development for mobilization of autologous and allogeneic peripheral blood stem cells are discussed.
Allogeneic peripheral blood stem cell transplantation.
  • T. Spitzer
  • Medicine, Biology
    The Journal of infusional chemotherapy
  • 1996
The use of mobilized peripheral blood stem cells (PBSC) for hematopoietic reconstitution following myeloablative chemoradiotherapy has been well shown to be an effective and probably superior
...
...